EP0633943A4 - Therapie genique utilisant des vecteurs viraux cibles. - Google Patents

Therapie genique utilisant des vecteurs viraux cibles.

Info

Publication number
EP0633943A4
EP0633943A4 EP93908659A EP93908659A EP0633943A4 EP 0633943 A4 EP0633943 A4 EP 0633943A4 EP 93908659 A EP93908659 A EP 93908659A EP 93908659 A EP93908659 A EP 93908659A EP 0633943 A4 EP0633943 A4 EP 0633943A4
Authority
EP
European Patent Office
Prior art keywords
gene therapy
viral vectors
targeted viral
targeted
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93908659A
Other languages
German (de)
English (en)
Other versions
EP0633943A1 (fr
Inventor
Alexander T Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0633943A1 publication Critical patent/EP0633943A1/fr
Publication of EP0633943A4 publication Critical patent/EP0633943A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C12N2810/856—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants from integrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP93908659A 1992-04-03 1993-03-31 Therapie genique utilisant des vecteurs viraux cibles. Withdrawn EP0633943A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40748 1979-05-21
US86279592A 1992-04-03 1992-04-03
US862795 1992-04-03
US4074893A 1993-03-29 1993-03-29
PCT/US1993/002957 WO1993020221A1 (fr) 1992-04-03 1993-03-31 Therapie genique utilisant des vecteurs viraux cibles

Publications (2)

Publication Number Publication Date
EP0633943A1 EP0633943A1 (fr) 1995-01-18
EP0633943A4 true EP0633943A4 (fr) 1997-05-02

Family

ID=26717389

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93908659A Withdrawn EP0633943A4 (fr) 1992-04-03 1993-03-31 Therapie genique utilisant des vecteurs viraux cibles.

Country Status (5)

Country Link
EP (1) EP0633943A4 (fr)
JP (1) JPH07505773A (fr)
AU (1) AU3940293A (fr)
CA (1) CA2133411A1 (fr)
WO (1) WO1993020221A1 (fr)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643756A (en) * 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
EP0670905B1 (fr) 1992-09-22 2003-07-23 Biofocus Discovery Limited Virus recombines presentant un polypeptide non-viral sur leur surface externe
JP3533219B2 (ja) * 1992-11-09 2004-05-31 アメリカ合衆国 標的指向ベクター粒子
ATE200105T1 (de) * 1994-05-13 2001-04-15 Chiron Corp Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen
US5753499A (en) * 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
WO1997024453A1 (fr) * 1995-12-28 1997-07-10 Chiron Corporation Polypeptides chimeres de surface virale, specifiques d'un recepteur, pour l'incorporation et l'interiorisation d'une particule et d'un virus dans des cellules cibles
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7026116B1 (en) 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US6140305A (en) 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
IL129922A0 (en) 1996-11-15 2000-02-29 Canji Inc Tissue specific expression of retinoblastoma protein
US6074850A (en) * 1996-11-15 2000-06-13 Canji, Inc. Retinoblastoma fusion polypeptides
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
ES2303726T3 (es) 1997-04-10 2008-08-16 University Of Southern California Proteinas modificadas que se fijan a componentes de la matriz extracelular.
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
DE1068357T1 (de) 1998-03-30 2001-07-19 Northwest Biotherapeutics Inc Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren
CN1629185B (zh) 1998-04-07 2011-11-02 科里克萨公司 结核杆菌抗原融合蛋白及其应用
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
DE19904800C1 (de) * 1999-02-05 2001-02-08 Eberhard Hildt Partikel zur Gentherapie
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
EP1161451A4 (fr) 1999-02-26 2006-05-17 Human Genome Sciences Inc Endokine alpha humain et methodes d'utilisation
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
AU5011400A (en) 1999-05-14 2000-12-05 Arbor Vita Corporation Molecular interactions in t cells
CA2387805C (fr) 1999-11-18 2012-08-28 Corvas International, Inc. Acides nucleiques codant pour des endotheliases, endotheliases et leurs utilisations
JP4729222B2 (ja) 1999-12-10 2011-07-20 ライフ テクノロジーズ コーポレーション 組換えクローニングにおける独自の選択性を有する複数の組換え部位の使用
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
EP2361635A3 (fr) 2000-08-30 2011-09-14 Pfizer Products Inc. Anti-IgE vaccins
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
EP2338512A1 (fr) 2000-11-28 2011-06-29 MedImmune, LLC Procédés d'administration/dosage d'anticorps anti-rsv pour la prophylaxie et le traitement
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
KR20030093316A (ko) 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 혈관 내피 성장 인자 ２
FI116851B (fi) 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
AU2002309647C1 (en) 2001-05-25 2008-09-11 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US7449562B2 (en) 2001-06-29 2008-11-11 Novartis Ag PERV screening method and use thereof
AU2002358631A1 (en) 2001-11-26 2003-06-10 Hybrigenics Protein-protein interactions in human immunodeficiency virus
EP1499352A4 (fr) 2002-04-12 2006-10-11 Medimmune Inc Anticorps anti-interleukine-9 recombinants
ES2443416T3 (es) * 2002-07-18 2014-02-19 Helix Biopharma Corp. Uso de ureasa para inhibir el crecimiento de células cancerosas
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
EP2298874A1 (fr) 2002-12-16 2011-03-23 Halozyme, Inc. Glycoprotéine de chondroitinase humaine (CHASEGP), son procédé de préparation et compositions pharmaceutiques le comportant
WO2004063351A2 (fr) 2003-01-09 2004-07-29 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
WO2004071462A2 (fr) 2003-02-12 2004-08-26 Johns Hopkins University Procede et composition pour le traitement d'infections virales utilisant l'interaction tsg101-vps28
PL1603541T5 (pl) 2003-03-05 2013-06-28 Halozyme Inc Rozpuszczalna glikoproteina o aktywności hialuronidazy (sHASEGP), sposób jej wytwarzania, zastosowanie i zawierające ją kompozycje farmaceutyczne
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
JP4895291B2 (ja) 2003-06-13 2012-03-14 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー Ｒｎａインターフェラーゼおよびその使用方法
AU2004259727A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases.
US20050221383A1 (en) 2003-08-08 2005-10-06 Choong-Chin Liew Osteoarthritis biomarkers and uses thereof
EP2272566A3 (fr) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation d'anticorps
EP1667710A2 (fr) 2003-10-03 2006-06-14 VIB vzw Methodes pour le recrutement de cellules souches
US20050227251A1 (en) 2003-10-23 2005-10-13 Robert Darnell Method of purifying RNA binding protein-RNA complexes
CN1926551B (zh) 2003-10-27 2010-06-16 罗斯塔生化科技有限责任公司 用于基因沉默的siRNA的设计方法
ES2533084T3 (es) 2003-12-23 2015-04-07 Genentech, Inc. Tratamiento del cáncer con anticuerpos monoclonales anti-IL 13 novedosos
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
CN101426489A (zh) 2004-04-16 2009-05-06 曹义海 抑制血管生成的成分和方法
WO2005113816A2 (fr) 2004-05-07 2005-12-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Methodes de diagnostic ou de traitement du cancer de la prostate au moyen du gene erg, seul ou combine a d'autres genes surexprimes ou sous-exprimes dans le cancer de la prostate
EP1766077B1 (fr) 2004-06-21 2012-03-28 The Board Of Trustees Of The Leland Stanford Junior University Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs
US20060003452A1 (en) * 2004-07-01 2006-01-05 Virxsys Corporation Vector packaging cell line
JP2008507540A (ja) 2004-07-21 2008-03-13 チューレン ユニバーシティ ヘルス サイエンス センター Ｐａｃａｐ化合物を用いる腎臓機能障害及び多発性骨髄腫の治療
CA2585717A1 (fr) 2004-10-27 2006-05-04 Medimmune Inc. Modulation d'une specificite d'anticorps par adaptation sur mesure de son affinite a un antigene apparente
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
NZ556158A (en) 2004-12-22 2010-04-30 Auckland Uniservices Ltd Trefoil factors and methods of treating proliferation disorders using same
CA2599589A1 (fr) 2005-02-07 2006-08-17 Genenews,Inc. Biomarqueurs de l'osteoarthrite benigne et utilisations
EP1869192B1 (fr) 2005-03-18 2016-01-20 MedImmune, LLC Rearrangement de l'infrastructure d'anticorps
WO2006113665A2 (fr) 2005-04-15 2006-10-26 Macrogenics, Inc. Di-anticorps covalents et leurs utilisations
AU2006279945B2 (en) 2005-08-10 2012-04-12 Macrogenics, Inc. Identification and engineering of antibodies with variant FC regions and methods of using same
TW200730825A (en) 2005-10-21 2007-08-16 Genenews Inc Method and apparatus for correlating levels of biomarker products with disease
KR20150055628A (ko) 2005-11-04 2015-05-21 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
US20090019557A1 (en) 2005-11-12 2009-01-15 Huda Akil Fgf2-related methods for diagnosing and treating depression
SG170819A1 (en) 2006-03-30 2011-05-30 Ptc Therapeutics Inc Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
EP2029173B1 (fr) 2006-06-26 2016-07-20 MacroGenics, Inc. Anticorps spécifiques du fc riib et leurs procédés d'utilisation
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
CA2661782C (fr) 2006-08-28 2019-04-16 La Jolla Institute For Allergy And Immunology Anticorps monoclonaux humains anti-hlight humain
JP5470041B2 (ja) 2006-10-10 2014-04-16 ザ ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド Ｅｒｇ遺伝子発現における前立腺癌特異的変化ならびにそれらの変化に基づく検出および治療方法
EP2407548A1 (fr) 2006-10-16 2012-01-18 MedImmune, LLC Molécules ayant des demi-vies réduites, compositions et leurs utilisations
EP2094282A4 (fr) 2006-11-15 2010-05-05 Functional Genetics Inc Anticorps anti-tsg101 et leurs utilisations pour le traitement des infections virales
JP5386364B2 (ja) 2006-12-18 2014-01-15 ジェネンテック， インコーポレイテッド 抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用
MX2009013816A (es) 2007-06-21 2010-02-24 Macrogenics Inc Diacuerpos covalentes y usos de los mismos.
JP2010534195A (ja) 2007-06-27 2010-11-04 オークランド ユニサーヴィスィズ リミテッド アルテミン及び関連するリガンドについてのポリペプチド及びポリヌクレオチド、並びにその使用方法
UA117446C2 (uk) 2007-08-29 2018-08-10 Санофі-Авентіс Гуманізоване антитіло до cxcr5
US8669349B2 (en) 2008-04-02 2014-03-11 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
EP2282770B1 (fr) 2008-06-04 2018-03-07 MacroGenics, Inc. Anticorps à liaison alteree à fcrn et leurs procedes d'utilisation
US8163497B2 (en) 2008-09-07 2012-04-24 Glyconex Inc. Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
SI2786762T1 (sl) 2008-12-19 2019-07-31 Macrogenics, Inc. Kovalentna diatelesa in njihove uporabe
EP2367564A1 (fr) 2008-12-22 2011-09-28 Universität Regensburg Utilisation de la protéine norrin dans le traitement de maladies associées à une augmentation de l'activité de tgf-bêta
JP5802195B2 (ja) 2009-04-27 2015-10-28 オタワ ホスピタル リサーチ インスティチュート 幹細胞を調節するための組成物および方法ならびにその使用
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
EA023179B1 (ru) 2009-08-13 2016-05-31 Круселл Холланд Б.В. Антитела против респираторного синцитиального вируса (pcb) и способы их применения
WO2011035205A2 (fr) 2009-09-18 2011-03-24 Calmune Corporation Anticorps dirigés contre candida, leurs collectes et procédés d'utilisation
US20120282266A1 (en) 2009-10-16 2012-11-08 Auckland Uniservices Limited Anti-neoplastic uses of artemin antagonists
WO2011054001A2 (fr) 2009-11-02 2011-05-05 The Administrators Of The Tulane Analogues de polypeptide d'activation d'adénylate cyclase hypophysaire (pacap) et procédés pour leur utilisation
WO2011057188A1 (fr) 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Anticorps anti-cd20 canins
WO2011101031A1 (fr) 2010-02-19 2011-08-25 Université de Liège Polynucléotide pour utilisation dans le traitement de maladies induites par l'influenzavirus a, codant pour une protéine mx modifiée, ladite protéine mx modifiée, et animal transgénique exprimant un gène codant pour une protéine mx modifiée
KR101896124B1 (ko) 2010-07-09 2018-09-07 얀센 백신스 앤드 프리벤션 비.브이. 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법
WO2012013249A1 (fr) 2010-07-30 2012-02-02 Université de Liège Protéine 1 de la matrice dentinaire (dmp1) pour l'utilisation dans des compositions pharmaceutiques
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2012094511A2 (fr) 2011-01-05 2012-07-12 Rhode Island Hospital Compositions et procédés destinés au traitement de lésion ou de maladie orthopédique
AU2012259162C1 (en) 2011-05-21 2020-05-21 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
CA2848851C (fr) 2011-09-16 2020-09-22 Ottawa Hospital Research Institute Compositions wnt7a et leurs procedes d'utilisation
CA2848841A1 (fr) 2011-09-16 2013-03-21 Fate Therapeutics, Inc. Compositions wnt et utilisations therapeutiques desdites compositions
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
WO2013120554A1 (fr) 2012-02-15 2013-08-22 Novo Nordisk A/S Anticorps qui se lient à la protéine 1 de reconnaissance de peptidoglycane
LT2814844T (lt) 2012-02-15 2017-10-25 Novo Nordisk A/S Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2014006063A2 (fr) 2012-07-02 2014-01-09 Medizinische Universität Wien Produit de séparation du complément c4d pour le traitement d'affections inflammatoires
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
WO2014120975A1 (fr) 2013-02-01 2014-08-07 California Institute Of Technology Immunocontraception à médiation par un anticorps
EP3110974A4 (fr) 2014-02-24 2018-01-24 Celgene Corporation Méthodes d'utilisation d'un activateur du céréblon pour l'expansion de cellules neurales et le traitement de troubles du système nerveux central
EP3888690A3 (fr) 2014-05-16 2021-10-20 MedImmune, LLC Molécules présentant une altération de liaison de récepteur fc néonatal ayant des propriétés thérapeutiques et diagnostiques améliorées
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
MY178347A (en) 2014-07-17 2020-10-08 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
CN117143814A (zh) 2014-11-17 2023-12-01 阿迪塞特治疗公司 工程化的γδ T细胞
WO2016191418A1 (fr) 2015-05-26 2016-12-01 Salk Institute For Biological Studies Vecteurs d'expression spécifiques de motoneurones
US9920100B2 (en) 2015-06-05 2018-03-20 The Chinese University Of Hong Kong Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy
WO2017182981A1 (fr) 2016-04-20 2017-10-26 Washington University Agoniste de ppar ou agoniste de lxr à utiliser pour traiter le lupus érythémateux systémique par modulation de l'activité lap
JP7210286B2 (ja) 2016-05-12 2023-01-23 アディセット バイオ， インコーポレイテッド γδＴ細胞集団の選択的増殖方法及びその組成物
SG11202004506WA (en) 2017-11-15 2020-06-29 Adicet Bio Inc METHODS FOR SELECTIVE EXPANSION OF d3 ?d T-CELL POPULATIONS AND COMPOSITIONS THEREOF
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
PE20201343A1 (es) 2018-04-02 2020-11-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y usos de los mismos
WO2020097261A1 (fr) 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nouvelles compositions et nouveaux procédés de traitement de globinopathies
WO2020117862A1 (fr) 2018-12-03 2020-06-11 Adicet Bio, Inc. Méthodes d'expansion sélective in vivo de populations de lymphocytes t gamma delta et compositions associées
WO2020243134A1 (fr) 2019-05-27 2020-12-03 Immatics US, Inc. Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
JP2023510195A (ja) 2020-01-03 2023-03-13 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 歯周の健康を促進するために局所投与されるｔｎａｐ
MX2022010461A (es) 2020-02-24 2022-12-13 Immatics Us Inc Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas.
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Ｃｄ８多肽、組合物及其使用方法
CN117157049A (zh) 2021-01-24 2023-12-01 迈克尔·大卫·福雷斯特 Atp合酶抑制剂-化妆品和治疗用途
WO2022240824A1 (fr) 2021-05-13 2022-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions et méthodes de traitement de drépanocytoses
WO2023004332A2 (fr) 2021-07-19 2023-01-26 New York University Compositions de vecteurs viraux adéno-associés et méthodes de promotion de la régénération musculaire
WO2023064255A2 (fr) 2021-10-15 2023-04-20 The Regents Of The University Of California Diagnostic et traitement de la thrombocytopénie induite par anti-pf4
WO2023081167A2 (fr) 2021-11-02 2023-05-11 The Regents Of The University Of California Mutants de p-sélectine et modulation de signalisation médiée par intégrine
AR128222A1 (es) 2022-01-07 2024-04-10 Johnson & Johnson Entpr Innovation Inc MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b
WO2023146807A1 (fr) 2022-01-25 2023-08-03 The Regents Of The University Of California Mutants de vegf et modulation de signalisation médiée par intégrine
WO2023200897A1 (fr) 2022-04-13 2023-10-19 The Regents Of The University Of California Utilisation d'il-6 virale dans le traitement du cancer
WO2023212691A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides récepteurs de tgfβ négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation
WO2023212655A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2024013727A1 (fr) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Matériau et procédés d'appariement amélioré par génie biologique de régions variables de liaison à l'antigène

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012087A1 (fr) * 1989-04-05 1990-10-18 Novacell Corporation Particule virale infectieuse ciblee a replication defectueuse
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
WO1992005266A2 (fr) * 1990-09-21 1992-04-02 Viagene, Inc. Cellules d'encapsidation
WO1992014829A1 (fr) * 1991-02-19 1992-09-03 The Regents Of The University Of California Particules virales agissant sur une gamme d'hotes modifiee
WO1993000103A1 (fr) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Proteines d'enveloppe chimeriques pour le ciblage de virus
WO1993005147A1 (fr) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Particules defectives interferentes du vih avec un cd-env chimerique
WO1993014188A1 (fr) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Virus cible

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012087A1 (fr) * 1989-04-05 1990-10-18 Novacell Corporation Particule virale infectieuse ciblee a replication defectueuse
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
WO1992005266A2 (fr) * 1990-09-21 1992-04-02 Viagene, Inc. Cellules d'encapsidation
WO1992014829A1 (fr) * 1991-02-19 1992-09-03 The Regents Of The University Of California Particules virales agissant sur une gamme d'hotes modifiee
WO1993000103A1 (fr) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Proteines d'enveloppe chimeriques pour le ciblage de virus
WO1993005147A1 (fr) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Particules defectives interferentes du vih avec un cd-env chimerique
WO1993014188A1 (fr) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Virus cible

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. MARTIN ET AL.: "Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurivirulent for mice", EMBO J., vol. 7, no. 9, September 1988 (1988-09-01), OXFORD UNIVERSITY PRESS,GB;, pages 2839 - 2847, XP002025309 *
B. GOUD ET AL.: "Antibody-mediated binding of a murine ecotropic miloney retroviral vector to human cells allows internalization but not the establishment of the proviral state", VIROLOGY, vol. 163, no. 3, March 1988 (1988-03-01), ACADEMIC PRESS, INC.,NEW YORK, US, pages 251 - 254, XP000613633 *
DONG J ET AL: "A CHIMERIC AVIAN RETROVIRUS CONTAINING THE INFLUENZA VIRUS HEMAGGLUTININ GENE HAS AN EXPANDED HOST RANGE", JOURNAL OF VIROLOGY, vol. 66, no. 12, 1 December 1992 (1992-12-01), pages 7374 - 7382, XP002011560 *
HIROSHI NEDA ET AL: "CHEMICAL MODIFICATION OF AN ECOTROPIC MURINE LEUKEMIA VIRUS RESULTS IN REDIRECTION OF ITS TARGET CELL SPECIFICITY", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 22, 5 August 1991 (1991-08-05), pages 14143 - 14146, XP000612122 *
S.D. LONDON ET AL.: "Infectious enveloped RNA virus antigenic chimeras", PROC. NATL.ACAD SCI., vol. 89, January 1992 (1992-01-01), NATL. ACAD SCI.,WASHINGTON,DC,US;, pages 207 - 211, XP002025310 *
See also references of WO9320221A1 *

Also Published As

Publication number Publication date
WO1993020221A1 (fr) 1993-10-14
EP0633943A1 (fr) 1995-01-18
CA2133411A1 (fr) 1993-10-14
AU3940293A (en) 1993-11-08
JPH07505773A (ja) 1995-06-29

Similar Documents

Publication Publication Date Title
EP0633943A4 (fr) Therapie genique utilisant des vecteurs viraux cibles.
EP0688358A4 (fr) Vecteurs ameliores en therapie genique
AU3972893A (en) Gene therapy using the intestine
EP0554376A4 (en) Dna construct for providing rna therapy
ZA961587B (en) Gene transfer-mediated angiogenesis therapy
HK1008979A1 (en) Gene transfer-mediated angiogenesis therapy
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
GB9524973D0 (en) Viral vectors
EP0625049A4 (fr) Transfert de genes ex vivo.
AU2552795A (en) Safe vectors for gene therapy
EP0789592A4 (fr) Therapie oculaire genique
EP0710123A4 (fr) Vecteurs d'adenovirus pour therapie genique
EP0679716A4 (fr) Signature genique.
AU2678097A (en) Targeted viral vectors
IL110284A0 (en) Viral vectors and their use in gene therapy
EP0666752A4 (fr) Microemulsions therapeutiques.
AU3434393A (en) Targeted virus
GB9622500D0 (en) Therapeutic gene
ZA945414B (en) DNA virus ribozymes
AU6014094A (en) Episomal vectors for gene therapy
AU1768192A (en) Rna delivery vector
EP0723460A4 (fr) Therapie genique concernant le systeme nerveux
OA09427A (en) "Viral treatment system".
GB9306386D0 (en) Gene expression
OA09664A (en) Virus/herbicide-resistance genes, processes for the preparation thereof and the use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941020

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970311

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990618

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020709